Overview
Novel Approaches to Secondary Prevention of Thrombotic Events in Peripheral Arterial Disease
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This enduring webcast shares highlights from a live presentation at the 16th Annual New Cardiovascular Horizons (NCVH) Conference in New Orleans on Friday, May 29, 2015.
Dr. Craig Walker and Dr. Pierluigi Tricoci discuss the atherothrombotic burden of PAD and the use of newer antiplatelet therapies for secondary prevention of CVD events in patients with PAD. The didactic content is supplemented by discussion of several case presentations.
Dr. Craig Walker and Dr. Pierluigi Tricoci discuss the atherothrombotic burden of PAD and the use of newer antiplatelet therapies for secondary prevention of CVD events in patients with PAD. The didactic content is supplemented by discussion of several case presentations.
This educational activity is designed for cardiologists, interventional cardiologists, vascular medicine specialists, cardiothoracic, endovascular, vascular and general surgeons, interventional radiologists and other healthcare professionals involved in the care and treatment of patients with peripheral arterial disease.
Peripheral arterial disease (PAD), an independent predictor of cardiovascular disease (CVD) morbidity and mortality, is associated with increased hospitalization costs, recurrent hospitalizations, and repeat revascularizations. Overall, patients with PAD have higher 1-year and 3-year hospitalization rates for vascular causes than those with other CVD. Adherence to guideline-recommended approaches, including antiplatelet therapy, significantly reduces the rates of major adverse limb events, major adverse cardiac events, and all-cause mortality. Select patient populations may require alternative and aggressive antiplatelet strategies to reduce recurrent events and rehospitalizations. This interactive activity will address selection of approaches to platelet inhibition for secondary prevention of CVD events in the PAD patient.
Upon completion of this activity, participants will be able to:
• Outline the burden and risks of atherothrombotic events in patients with PAD
• Review the mechanisms of action of antiplatelet therapies for optimal postsurgical management of PAD
• Compare and contrast strategies for secondary prevention via platelet inhibition to reduce risks of PAD and CVD
• Outline the burden and risks of atherothrombotic events in patients with PAD
• Review the mechanisms of action of antiplatelet therapies for optimal postsurgical management of PAD
• Compare and contrast strategies for secondary prevention via platelet inhibition to reduce risks of PAD and CVD
This activity is supported by an educational grant from Merck & Company
Dr. Craig Walker and Dr. Pierluigi Tricoci discuss the atherothrombotic burden of PAD and the use of newer antiplatelet therapies for secondary prevention of CVD events in patients with PAD. The didactic content is supplemented by discussion of several case presentations.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem while viewing any media (audio/video).
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
5. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
6. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
5. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
6. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Craig M. Walker, MD, FACC, FACA, FACP, FSCAI, FASCI, FCCP, FICA
Founder, President and Medical Director,
Cardiovascular Institute of the South
Clinical Professor of Medicine
Tulane University School of Medicine
LSU School of Medicine
New Orleans, Louisiana
Pierluigi Tricoci, MD, PhD, MHS
Assistant Professor of Medicine, Cardiology
Duke University School of Medicine
Durham, North Carolina
Founder, President and Medical Director,
Cardiovascular Institute of the South
Clinical Professor of Medicine
Tulane University School of Medicine
LSU School of Medicine
New Orleans, Louisiana
Pierluigi Tricoci, MD, PhD, MHS
Assistant Professor of Medicine, Cardiology
Duke University School of Medicine
Durham, North Carolina
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity. ACHL also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity.
Craig M. Walker, MD, FACC, FACA, FACP, FSCAI, FASCI, FCCP, FICA (Chair)
Advisory Board: Abbott, CR Bard, Boston Scientific, and Spectranetics
Consulting Agreements: Abbott, Boston Scientific, Cardiva Medical, Cook Medical, Lake Regional, Medtronic, and Spectranetics
Stockholder: Cardiva Medical, Cardioprolific, Spectranetics, and Vasamed
Honoraria Agreements: Abbott, Bard, Boston Scientific, Spectranetics, and Trireme Medical
Speakers' Bureau: Abbott, Arbor, Bard, Boehringer-Ingelheim, Bristol-Myers Squibb/Sanofi Pharmaceutical, Cardiva Medical, Cordis, DSI/Lilly, Pfizer, and Spectranetics
Pierluigi Tricoci, MD, PhD, MHS (Faculty)
Consulting Agreement/Institutional Research Recipient: Merck & Company
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
The following disclosure information has been provided:
Craig M. Walker, MD, FACC, FACA, FACP, FSCAI, FASCI, FCCP, FICA (Chair)
Advisory Board: Abbott, CR Bard, Boston Scientific, and Spectranetics
Consulting Agreements: Abbott, Boston Scientific, Cardiva Medical, Cook Medical, Lake Regional, Medtronic, and Spectranetics
Stockholder: Cardiva Medical, Cardioprolific, Spectranetics, and Vasamed
Honoraria Agreements: Abbott, Bard, Boston Scientific, Spectranetics, and Trireme Medical
Speakers' Bureau: Abbott, Arbor, Bard, Boehringer-Ingelheim, Bristol-Myers Squibb/Sanofi Pharmaceutical, Cardiva Medical, Cordis, DSI/Lilly, Pfizer, and Spectranetics
Pierluigi Tricoci, MD, PhD, MHS (Faculty)
Consulting Agreement/Institutional Research Recipient: Merck & Company
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
To receive credit, participants are required to complete the pre-test, view the online webcast, achieve at least 65% on the post-test and complete the evaluation form. A certificate will be immediately available after completing the stated requirements. There is no fee to participate in the activity or for the generation of the certificate.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 203.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 203.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.